Publications by authors named "Brieuc Cherel"

Claim this Profile
C
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.
Gabriel Brisou, Jérôme Paillassa, Sophie Bernard, Olivier Tournilhac, Luc-Matthieu Fornecker, Brieuc Cherel

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.
Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Brieuc Cherel

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program.
Aurore Perrot, Cyrille Hulin, Ariane Boumendil, Hamza Manjra, Antoine Leveque, Brieuc Cherel

Haematologica· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot, Brieuc Cherel

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension.
Brieuc Cherel, Marc Humbert, Francis R LeBlanc, Renato Zambello, Mohamed Hamidou

Chest· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis